MediWound Ltd. Signed A Scale-Up Agreement With Biopharmax Group Ltd. To Establish A State-Of-The-Art Manufacturing Facility And Increase Production Capacity To Meet The Growing Global Demand For Nexobrid; Estimated $12M Will Be Invested In The Project
Portfolio Pulse from Happy Mohamed
MediWound Ltd. has signed a scale-up agreement with Biopharmax Group Ltd. to establish a state-of-the-art manufacturing facility and increase production capacity to meet the growing global demand for Nexobrid. An estimated $12M will be invested in the project.
July 17, 2023 | 8:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MediWound's partnership with Biopharmax to increase Nexobrid production could potentially boost its revenues and profitability.
The news directly pertains to MediWound as it has signed a scale-up agreement with Biopharmax. This partnership is expected to increase the production of Nexobrid, which could lead to increased sales and revenues for MediWound. Therefore, this news is likely to have a positive impact on MediWound's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100